Details of the Drug

General Information of Drug (ID: DM1CI9R)

• Drug Name: Bempedoic acid
• Synonyms: ETC-1002; bempedoic acid; 738606-46-7; 8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid; ESP-55016; UNII-1EJ6Z6Q368; ETC 1002; Bempedoic acid; ESP-55016; 1EJ6Z6Q368; Bempedoate; Bempedoic acid [USAN:INN]; ETC1002; ESP 55016; Bempedoic acid (USAN/INN); SCHEMBL185768; GTPL8321; CHEMBL3545313; HYHMLYSLQUKXKP-UHFFFAOYSA-N; EX-A1243; ZINC3948738; BCP16083; s7953; AKOS027439916; CS-3952; DB11936; AK499358; AC-29040; AS-49804; HY-12357; Bempedoic Acid(ETC-1002;ESP-55016); D10691; Pentadecanedioic acid, 8-hydroxy-2,2,14,14-tetramethyl-

Indication

Disease Entry	ICD 11	Status	REF
Familial hypercholesterolemia	5C80.00	Approved	[1]
Cardiovascular disease	BA00-BE2Z	Phase 3	[2]

• ATC Code:
  C10AX15: Bempedoic acid
  C10AX: Other lipid modifying agents
  C10A: LIPID MODIFYING AGENTS, PLAIN
  C10: LIPID MODIFYING AGENTS
  C: CARDIOVASCULAR SYSTEM
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 344.5
  Logarithm of the Partition Coefficient (xlogp); 4.8
  Rotatable Bond Count (rotbonds); 14
  Hydrogen Bond Donor Count (hbonddonor); 3
  Hydrogen Bond Acceptor Count (hbondacc); 5
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 3.5 h [3]
  Clearance: The clearance of drug is 11.2 mL/min [3]
  Elimination: The drug are primarily eliminated via the urine (70%) and the feces (30%) [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 15 - 24 hours [4]
  Metabolism: The drug is metabolized via the metabolism of its acyl glucuronide [5]
  Vd: The volume of distribution (Vd) of drug is 18 L [3]
• Chemical Identifiers:
  Formula: C19H36O5
  IUPAC Name: 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
  Canonical SMILES: CC(C)(CCCCCC(CCCCCC(C)(C)C(=O)O)O)C(=O)O
  InChI: InChI=1S/C19H36O5/c1-18(2,16(21)22)13-9-5-7-11-15(20)12-8-6-10-14-19(3,4)17(23)24/h15,20H,5-14H2,1-4H3,(H,21,22)(H,23,24)
  InChIKey: HYHMLYSLQUKXKP-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 10472693
  ChEBI ID: CHEBI:149601
  CAS Number: 738606-46-7
  UNII: 1EJ6Z6Q368
  DrugBank ID: DB11936
  TTD ID: D0D9NY
  ACDINA ID: D00867
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ATP-citrate synthase (ACLY)	TT0Z6Y2	ACLY_HUMAN	Inhibitor	[1]
Cholesterol synthesis (Chole synth)	TTRA79S	NOUNIPROTAC	Inhibitor	[1]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Bempedoic acid (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
ABT-492	DMJFD2I	Major	Increased risk of tendinitis/tendon rupture by the combination of Bempedoic acid and ABT-492.	Bacterial infection [1A00-1C4Z]	[6]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Bempedoic Acid 180mg tablet	180mg	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] FDA Approved Products: Nexletol (bempedoic acid) oral tablets
• [4] Bempedoic Acid (ETC-1002): A Current Review. Cardiol Clin. 2018 May;36(2):257-264. doi: 10.1016/j.ccl.2017.12.007. Epub 2018 Feb 21.
• [5] Walker CJ, Cowan DA, James VH, Lau JC, Kicman AT: Doping in sport: 3. Metabolic conversion of oral norethisterone to urinary 19-norandrosterone. Steroids. 2009 Mar;74(3):341-9. doi: 10.1016/j.steroids.2008.11.008. Epub 2008 Nov 19.
• [6] Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.